Table 3.
Comparison of baseline characteristics before and after MAIC
| Trial/Study | Race (White) | Male | Median age | ECOG = 0 | No mutation | PCyR | MCyR | Resistance | Intolerance | Prior TKIs | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nilotinib/dasatinib | Nilotinib/dasatinib | TKIs = 2 | |||||||||||
| Comparison: asciminib vs ponatinib (cohort A + B) | |||||||||||||
| PACE | N = 270 | 80.9% | 53.3% | 60 | 70.0% | 51.1% | 19.6% | – | 79.6% | – | 14.4% | - | 33.7% |
| ASCEMBL – pre-MAIC | N = 103 | 71.8% | 43.7% | 53 | 76.7% | 86.4% | 24.3% | – | 69.9% | – | 39.8% | – | 53.4% |
| ASCEMBL – post-MAIC | ESS = 31 | 76.5% | 34.6% | 60 | 70.0% | 51.1% | 19.6% | – | 79.6% | – | 14.4% | – | 33.7% |
| Comparison: asciminib vs ponatinib (cohort A) | |||||||||||||
| PACE | N = 203 | 85.7% | 46.8% | 61 | 68.5% | 67.0% | 19.2% | – | – | – | – | – | 31.5% |
| ASCEMBL – pre-MAIC | N = 103 | 71.8% | 43.7% | 53 | 76.7% | 86.4% | 24.3% | – | – | – | – | – | 53.4% |
| ASCEMBL – post-MAIC | ESS = 53 | 73.9 | 42.3 | 61 | 68.5% | 67.0% | 19.2% | – | – | – | – | – | 31.5 |
| Comparison: asciminib vs nilotinib | Imatinib | Dasatinib | Imatinib | Dasatinib | TKIs = 2 | ||||||||
| Giles et al. 2010 | N = 39 | – | – | 62 | 64% | 33% | – | 21% | 85% | 31% | 15% | 67% | 100% |
| ASCEMBL – pre-MAIC | N = 157 | – | – | 52 | 80% | 87% | – | 28% | 54% | 45% | 54% | 35% | 52% |
| ASCEMBL – post-MAIC | ESS = 48 | – | – | 53 | 77% | 95% | – | 21% | 32% | 31% | 74% | 67% | 100% |
| Comparison: asciminib vs dasatinib | Imatinib | Nilotinib | Imatinib | Nilotinib | TKIs = 2 | ||||||||
| Rossi et al. 2013 | N = 34 | – | 27% | 60 | – | 50% | – | – | 94% | 59% | 6% | 50% | 100% |
| ASCEMBL – pre-MAIC | N = 157 | – | 52% | 52 | – | 87% | – | – | 54% | 38% | 54% | 23% | 43% |
| ASCEMBL – post-MAIC | ESS = 61 | − | 53% | 46 | – | 79% | – | – | 42% | 59% | 39% | 12% | 100% |
| Comparison: asciminib vs dasatinib | |||||||||||||
| Tan et al. 2019 | N = 24 | – | 63% | 50 | – | 54% | – | – | – | 59% | – | 50% | 100% |
| ASCEMBL – pre-MAIC | N = 157 | − | 52% | 52 | – | 87% | – | – | – | 38% | – | 23% | 43% |
| ASCEMBL – post-MAIC | ESS = 23 | − | 63% | 50 | – | 54% | – | – | – | 59% | – | 50% | 100% |
| Comparison: asciminib vs nilotinib/dasatinib | Nilotinib/dasatinib | Nilotinib/dasatinib | TKIs = 2 | ||||||||||
| Ibrahim et al. 2010 | N = 26 | – | 54% | 64 | – | 54% | – | – | 27% | – | 65% | – | 100% |
| ASCEMBL – pre-MAIC | N = 103 | – | 44% | 53 | – | 86% | – | – | 70% | – | 40% | – | 53% |
| ASCEMBL – post-MAIC | ESS = 35 | – | 44% | 51 | – | 92% | – | – | 27% | – | 65% | – | 100% |
ECOG Eastern Cooperative Oncology Group; ESS effective sample size; MAIC matching-adjusted indirect comparison; MCyR major cytogenetic response; PCyR partial cytogenetic response; TKI tyrosine kinase inhibitor